Focused On-demand Library for Carbonic anhydrase 4

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P22748

UPID:
CAH4_HUMAN

ALTERNATIVE NAMES:
Carbonate dehydratase IV; Carbonic anhydrase IV

ALTERNATIVE UPACC:
P22748; B4DQA4; Q6FHI7

BACKGROUND:
Carbonic anhydrase 4 is essential for pH regulation, converting carbon dioxide to bicarbonate and protons. This enzyme's function is vital for the acid-base balance in various tissues, including the retina, where it prevents acid overload, safeguarding visual function.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Carbonic anhydrase 4 could open doors to potential therapeutic strategies for Retinitis pigmentosa 17, a disease marked by severe visual impairment. Targeting this enzyme offers a promising avenue for mitigating the progression of this retinal dystrophy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8572 of 8789